Poseida Therapeutics Acquisition Agreement with Roche for Up to $1.5 Billion
Poseida Therapeutics, a company specializing in allogeneic cell therapy and genetic medicines for patients with various health conditions, recently announced an exciting merger agreement with Roche. Under this agreement, Roche will acquire Poseida for up to $1.5 billion. The deal includes a cash payment of $9 per share at closing, along with a contingent value right that could pay out an additional $4 per share based on reaching certain milestones. This transaction is a significant milestone for both companies and is expected to be finalized in the first quarter of 2025.
Leading the legal team for this merger were Rowook Park, Barbara Borden, and Julia Kim from Cooley. They worked closely with Rajdeep Bains, Josh Himmelstern, Elaine Huang, Anne Luquette, Allie Pilmer, and Novak Topalovic to facilitate this important agreement. Cooley has a strong history of working with Poseida, having supported them through their initial public offering, various financial transactions, and collaboration agreements, including the one with Roche.
Cooley LLP, the legal firm behind this deal, is known for its expertise in handling transformative deals, intellectual property matters, and high-stakes litigation. With over 1,300 lawyers in 19 offices across the United States, Asia, and Europe, Cooley brings a wealth of experience and knowledge to every client engagement. Their total workforce of nearly 3,000 ensures that clients receive top-notch legal support on a global scale.
